INTRODUCTION
Neglected tropical diseases (NTDs), although not well known in high-income countries, cause severe physical and economic burdens in low-income countries. 1 Recent experiences in co-implementing and integrating NTD program activities have shown progress toward achieving programmatic and cost efficiencies. Two of the diseases included in integrated programs, lymphatic filariasis (LF) and soil-transmitted helminthiasis (STH), are endemic to Haiti. Both infections can be controlled through preventive chemotherapy programs that target at-risk populations with annual distribution of diethylcarbamazine (DEC) and albendazole.
Haiti is the poorest country in the Western Hemisphere. It had a 2008 gross national income per capita of U.S. $660, and 55% of the population lived below the international poverty line (U.S. $1.25 a day). 2 Access to health care is challenging for most Haitians; only 47% of the population are served by the national health system. Haiti's national health system includes networks of local health units, community hospitals operated by the government and nongovernmental organizations (NGOs), departmental reference hospitals, and university hospitals. The health network is organized into 54 communal health units, each serving a population of 80,000-140,000 inhabitants and responsible for offering a minimum package of services and for coordinating the local health units. However, inadequate human and financial resources throughout the Haitian health system result in serious problems in functionality, organization, management, and quality control at all levels. In addition, many health services provided by the private sector, particularly the nonprofit sector, are often poorly integrated with public services. 3 Haiti has the highest prevalence of LF infection in the Western Hemisphere. The Haitian Ministry of Public Health and Population (MSPP) conducted a national survey of LF prevalence in 2001 by using an assay to detect the presence of filarial antigen in the blood among school children 6-11 years of age. Among Haiti's 133 communes, 117 (87.9%) met the World Health Organization (WHO) criteria for implementing mass drug administration (MDA) to treat LF; an antigen prevalence > 1%. 4 Given internal population migration, Haiti's current national strategy is to implement MDA in all communes.
The prevalence of LF in Haiti by commune is shown in Figure 1 . The lightest areas represent high-prevalence zones in which MDA had occurred. The darkest areas represent highprevalence zones in which MDA had not yet begun.
The prevalence of STH among school age children in Haiti is shown by department in Figure 2 . In 2002, it ranged from 21% in Center Department to 74% in Grande Anse Department. All departments have prevalence rates above the threshold for mass treatment, according to WHO guidelines. 5 Antifilarial medications such as albendazole are known to have an effect on helminths, such as Ascaris , Trichuris , and hookworm. Studies on the impact of antifilarial medications in sentinel research areas of Leogane, in the West Department, where mass treatment with DEC and albendazole was conducted, showed a significant decrease in the intensity of Ascaris , Trichuris , and hookworm infections. 6 The MSPP established the LF program in 2001, approximately one year after the establishment of the STH program in 2000, with the objectives of reducing LF prevalence to the point of elimination and controlling STH. Preventive chemotherapy is an important component of both programs. Since their establishment, these programs have been underfunded and have relied on external partners to aid in implementation.
In 2008, Haiti formed a national NTD program, Projet des Maladies Tropicales Negligées (MTN), which consolidated plans for scaling up the elimination of LF and control of STH with a joint strategic plan. This joint strategy resulted in increasing school-based distribution platforms and community-based LF drug distributions, developing social mobilization materials with integrated disease control and hygiene messages, and pooling resources of staff from the MSPP LF and Family Health Programs to support MDA training, supervision, and monitoring activities. In 2008-2009, the MTN Program treated 55 of 134 diseaseendemic communes for at least one of the two diseases, with plans to reach full national coverage during 2011.The MTN Program uses community leaders, promoters, teachers, and distributors to mobilize the population and deliver preventive chemotherapy for LF and STH. Diethylcarbamazine and albendazole are delivered once a year through MDA at community distribution posts and elementary schools. Each post is equipped to serve at least 800 persons over 4-5 days of mass treatment with a staff of three community drug distributors per post. One or two community leaders per section are responsible for leading information, education, and communication activities; choosing distribution sites; and training promoters and drug distributors. Community promoters supervise 2-3 distribution sites and help implement information, education, and communication activities directly before MDA. In schools, 2-3 teachers per institution distribute drugs over the course of 2-3 hours. These teachers have been trained by the directors of the schools, who in turn have been trained by zonal school inspectors working for the Ministry of Education.
All persons greater than two years of age are targeted for treatment except pregnant mothers and the infirm. Children of school age are primarily targeted through school-based distributions. Community-based distributions target children 2-5 years of age, school-age children not reached through schoolbased distributions, and adults.
The goal of this study was to provide data on the cost of implementing the MTN Program in 2008-2009. Although not a specific goal, one also may make some interesting inferences to data from a cost study conducted in 2002. Who pays? What is the cost distribution by activity? Which activities consume the largest amount of resources? Methods followed previous protocols developed for cost data collection for LF elimination programs and subsequent NTD integration projects. 9, 10 Perspective. The analysis was prepared from the perspective of the Haitian MTN Program. In Haiti, nongovernmental partners are responsible for implementing the program in selected geographic areas on behalf of the national government. In-country resources incurred by NGOs participating in the MDA campaigns were taken into account, but their overseas management and administrative costs were not included. The analysis included in-country costs for IMAWH and HSC, which were provided by USAID and the Bill and Melinda Gates Foundation, respectively. Level of analysis and sampling frame. The MDA targeted a total of 55 communes. Of these communes, 10 were chosen for the cost analysis. The costing exercise gathered information from the government and NGO partners at the national and commune levels. The 10 communes were selected by dividing the 55 communes targeted for MDA into 10 geographic clusters of approximately 5 communes each, which were then ranked randomly. Two communes were chosen randomly from each of the five clusters that appeared at the top of the ranked list. After a consultation with partners, some communes were changed to ensure more equal distribution of the study communes among the implementing partners.
One of the communes is considered primarily urban, five are peri-urban, and four are rural. Four of the communes selected were implementing an MDA campaign for the first time. The other six communes previously had implemented an average of 3.5 MDAs, with coverage rates that ranged from 34% to 81% ( Table 1 ) . Coverage rates are defined as epidemiologic coverage, which is the number of persons reported to have ingested the drugs divided by the total at-risk population in the commune; and as program coverage, which is the number of persons reported to have ingested the drugs divided by the total population eligible to take the drugs.
MDA coverage information for the IMAWH/UND commune of Limbe/Bas Limbe was obtained, but data were not available for costs of implementing MDA in these communes. Thus, they were excluded from the cost analysis.
The Data collection. Administrators and finance staff working for the MTN Program, IMAWH, UND, and HSC provided retrospective cost information to a single interviewer. Costs were collected in 12 NTD program activity categories: advocacy, mapping, social mobilization and education, training, drug distribution, field supervision, data management, monitoring and evaluation, planning, procurement, morbidity control and surgery, and other (tasks included in the activity categories) ( Table 2 ). Because the MTN Program does not include latrine construction and vector control, those categories were not included. Morbidity control and surgery costs were collected as part of overall program costs. However, for this report, we excluded them because our focus is on costs related only to MDA. In addition, because no sentinel sites were active in 2008-2009, there were no sentinel site costs to be included in the monitoring and evaluation category.
Costs were also categorized by input: personnel, per diem, travel/transportation, equipment/facilities, supplies and other recurrent operating costs, and intervention drugs. Drugs for serious adverse effects were purchased as supplies by HSC and MSPP; those obtained by IMAWH were donated. The information concerning human resources devoted to NTDs was gathered through retrospective interviews (short questionnaire) of selected staff from implementing organizations. Measurement of volunteer time was not included in the cost analysis.
Per diems issued to MDA volunteers (e.g., community leaders, promoters, distributors, and school inspectors) were included in the analysis. The analysis did not include in-kind or opportunity costs to the people receiving drugs through the MDA campaigns.
Capital costs, defined as items with a life expectancy of more than one year, were collected for transport (vehicles), equipment (computers and printers), and facilities inputs. These costs were annualized by using a procedure that included years of useful life, scrap value, and a discount rate of 3%. 10 The cost data were collected in U.S. dollars and Haitian Gourdes, which were converted to U.S. dollars by using historical exchange rate information calculated during the study period ( , as in the case of training, which is a separate category in this study but was included in the social mobilization and MDA categories listed in the report by de Rochars et al. 8 Adverse event treatment was a separate activity category in 2002, but in the recent cost study, the acquisition of the adverse event drugs was considered part of the expenditures for the delivery and distribution of the intervention.
The 2002 cost analysis used the same input categories as the current study, with one exception; per diem for programrelated activities was included in personnel costs. Subsequent protocols have separated it from other categories because it is easier to gather independently and represents an important Data analysis. The data collected were entered into a Microsoft (Redmond, WA) Access database and extracted to Microsoft Excel for analysis. Retrospective survey data from program employees provided the proportion of time each employee dedicated to NTD activities. This proportion was used to calculate the salary amount included for each staff member as costs to the MTN Program. For each implementing partner, the size of the population treated in the study communes was divided by the size of the population in all communes to calculate a proportion of salary costs applicable to the study communes ( Table 3 ) .
In addition, for IMAWH, cost data were collected in aggregate for all communes in which MDA was implemented in 2008-2009. Therefore, this proportion was applied to all costs collected. For HSC and MSPP, costs other than staff annual compensation were collected for the study communes only.
The proportion of study costs applicable to the study communes for each partner was also used to allocate the cost per partner of a coverage study conducted in February 2009 after completion of the MDA. Designed by CDC and funded by USAID, the Bill and Melinda Gates Foundation, UND, and CDC, the study collected data in 10 communes. The results for this study will be reported elsewhere.
The percentage of time devoted to NTD activities collected in the retrospective personnel interview was applied to other input categories, such as transportation, recurrent costs for supplies, and recurrent and capital costs for facilities and equipment for IMAWH and HSC, which were collected at an organization level. Information about per diem was collected by activity. All drug costs were allocated to the procurement activity as an input.
To obtain drug costs, the size of the population treated (collected from MSPP coverage data) was used to calculate the amount of the DEC and albendazole distributed during the MDA. The multiplier used for DEC was 6.9 tablets per person and was derived from an analysis of previous patterns of drug distribution in Haiti. The Haiti MTN Program used 50-mg tablets, and the dose per person ranged from 50 mg to 400 mg, depending on age. 5 The multiplier used for albendazole was 1.1, which included the standard 10% excess to account for wastage (GlaxoSmithKline, unpublished data). The drug costs were calculated using the following data: U.S. $0.036 per DEC tablet distributed by IMAWH (IMAWH, unpublished data), U.S. $0.0048 per DEC tablet purchased by UND for distribution by HSC and MSPP (UND, unpublished data), and U.S. $0.19 per albendazole tablet (GlaxoSmithKline, unpublished data). GlaxoSmithKline changed the valuation of the donated albendazole in late 2008 (published in 2009) to U.S. $0.045 per tablet. Because the drugs were obtained before that date, we have used the earlier valuation (GlaxoSmithKline, unpublished data.)
The summary measure calculated is the cost per person treated. We report it in two ways: 1) program costs, which include the costs of transportation, supplies, equipment, and facilities (if applicable); and the cost of DEC. 2) Economic costs include those inputs, as well as the value of the albendazole donation. Table 4 .
RESULTS
Taking the economic costs into account, which include the cost of donated albendazole, we estimated the MDA cost to be U.S. $403,000 and the average economic cost per person treated as U.S. $0.64. The economic cost for treating 2,890,719 persons in the 55 MDA communes was approximately U.S. $1,850,060. The drugs represented 37% of the total.
For program costs, most resources were dedicated to the activities of delivery and distribution (50%), training (15%), and field supervision (8%, which could have covered supervision of either of the two previous activities). Distribution of program costs by activity is shown in Figure 3 .
The most substantial inputs included per diem (35% of total economic costs and 52% of program costs), supplies and other recurrent costs (14% of total economic costs and 21% of program costs), and personnel (7% of total economic costs and 11% of program costs). Per diem costs to volunteers and program personnel for drug distribution were 69% of total drug distribution costs. The analysis included four IMAWH personnel (program manager, driver, accountant, and pharmacist/logistician), five HSC personnel (program director, administrator, depot manager, education officer, and accounting administrator), and six national government personnel (national coordinator, national coordinator for education, administrator, nurse program supervisor, nurse evaluation officer, and nurse communications officer). These inputs as a proportion of total economic and program costs are shown in Table 5 . Economic costs shown in US dollars, disaggregated by inputs and activities, are shown in Table 6 . Sensitivity analysis. The inputs that consumed the highest proportion of resources, excluding the costs of the donated drugs, included per diem (51%), supplies and other recurrent costs (21%), and personnel (11%). We performed sensitivity analyses to assess how much changes in the value of these inputs would affect overall results. Each input was increased between 10% and 300%. The results for all three at 300% were U.S. Limitations. This study set out to collect cost data for 10 communes. Nine are included in this analysis because the data available from IMAWH did not include costs for Limbe/ Bas Limbe, which were funded at the time by UND. Capital costs, which tend to be low in these programs, could have been underreported, particularly those capital costs of MSPP. Because some of the commune-level cost data came from the central level and the partners sought to maximize costs with joint activities, it was difficult to produce differential estimates at the commune level.
The study did not report a per person cost per commune because not all partners carried out their activities in the same way. Certain partners minimized costs through joint activities, involving groups of communes at one time, particularly training. Thus, there was no effort to explore cost per person and coverage per commune. All three partners reported aggregate coverage rates that were above the WHO-recommended 65% of total population coverage.
DISCUSSION
The differences in the cost per person treated among the partners can be attributed in part to start-up costs associated with implementing the first round of MDA in some communes. IMAWH had slightly higher program costs (U.S. $0.50 Table 5 Inputs as a percentage of total economic and program costs, Haiti The current study documents participation by the MTN Program in an environment where the country's fragile health system depends greatly on outside organizations. Government contribution to LF programs in the LFSC cost analysis ranged from 9% to 99%, with an average of approximately 56% for 5 of the 7 participating countries (there were no data for Haiti). The current contribution of 10.3% for Haiti is similar to the 9% reported by the Dominican Republic in the earlier study. The change in the valuation of albendazole will have a substantial effect on economic costs. In the MDA reported here, the drugs would represent 12% of the costs, including the value of the donated drugs, amounting to a reduction of 25%; the economic cost per person treated would have been reduced to U.S. $0.47. This finding means that with the new valuation, the economic cost to achieve full geographic MDA coverage in 2008-2009 would have been reduced to close to U.S. $3 million.
This study restricted the costing analysis to the costs from the perspective of the national program, enabling governments to assess the cost to the national health system of implementing an MDA. Nonetheless, donor management and administrative and pharmaceutical drug costs associated with running a donor-supported program also are significant and often critical to the implementation of many programs. It is recommended that this perspective be addressed in future studies. It is hoped the results of this study will serve as a reference to implementing partners for tracking and analyzing cost trends and evaluating program progress and results. Received November 9, 2010. Accepted for publication July 6, 2011.
